| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cardiac Surgical Procedures | 25 | 2023 | 268 | 3.610 |
Why?
|
| Heart Valve Prosthesis Implantation | 24 | 2021 | 171 | 3.270 |
Why?
|
| Heart Valve Diseases | 12 | 2023 | 93 | 1.820 |
Why?
|
| Aortic Valve | 14 | 2021 | 181 | 1.670 |
Why?
|
| Heart-Assist Devices | 8 | 2019 | 158 | 1.390 |
Why?
|
| Mitral Valve | 10 | 2023 | 126 | 1.320 |
Why?
|
| Postoperative Complications | 19 | 2021 | 1314 | 1.250 |
Why?
|
| Coronary Artery Bypass | 14 | 2023 | 292 | 1.230 |
Why?
|
| Mitral Valve Insufficiency | 6 | 2021 | 98 | 0.990 |
Why?
|
| Circulatory Arrest, Deep Hypothermia Induced | 4 | 2014 | 5 | 0.980 |
Why?
|
| Heart Valve Prosthesis | 9 | 2021 | 106 | 0.910 |
Why?
|
| Intraoperative Complications | 4 | 2019 | 89 | 0.900 |
Why?
|
| Aorta, Thoracic | 4 | 2016 | 80 | 0.880 |
Why?
|
| Cardiopulmonary Bypass | 8 | 2014 | 58 | 0.800 |
Why?
|
| Vascular Surgical Procedures | 3 | 2015 | 240 | 0.800 |
Why?
|
| Reoperation | 12 | 2020 | 300 | 0.800 |
Why?
|
| Aortic Valve Stenosis | 7 | 2020 | 190 | 0.790 |
Why?
|
| Hospital Mortality | 12 | 2021 | 873 | 0.750 |
Why?
|
| Retrospective Studies | 48 | 2021 | 6823 | 0.720 |
Why?
|
| Treatment Outcome | 41 | 2023 | 5773 | 0.700 |
Why?
|
| Heart Failure | 6 | 2019 | 949 | 0.690 |
Why?
|
| Sternum | 6 | 2021 | 29 | 0.690 |
Why?
|
| Aged | 57 | 2021 | 14879 | 0.670 |
Why?
|
| Prosthesis Failure | 6 | 2021 | 78 | 0.650 |
Why?
|
| Middle Aged | 58 | 2021 | 18163 | 0.630 |
Why?
|
| Bioprosthesis | 6 | 2021 | 38 | 0.620 |
Why?
|
| Prosthesis Design | 10 | 2021 | 218 | 0.620 |
Why?
|
| Risk Assessment | 12 | 2021 | 2091 | 0.610 |
Why?
|
| Aortic Valve Insufficiency | 2 | 2012 | 42 | 0.610 |
Why?
|
| Sternotomy | 4 | 2021 | 12 | 0.600 |
Why?
|
| Minimally Invasive Surgical Procedures | 8 | 2020 | 126 | 0.590 |
Why?
|
| Humans | 91 | 2023 | 64818 | 0.590 |
Why?
|
| Intra-Aortic Balloon Pumping | 3 | 2014 | 19 | 0.580 |
Why?
|
| Male | 69 | 2021 | 30880 | 0.580 |
Why?
|
| Calcinosis | 1 | 2019 | 84 | 0.570 |
Why?
|
| Female | 71 | 2021 | 33854 | 0.560 |
Why?
|
| Echocardiography, Transesophageal | 8 | 2021 | 117 | 0.560 |
Why?
|
| Pulmonary Embolism | 5 | 2018 | 196 | 0.530 |
Why?
|
| Aorta | 4 | 2018 | 108 | 0.520 |
Why?
|
| Blood Vessel Prosthesis Implantation | 3 | 2020 | 276 | 0.490 |
Why?
|
| Aortic Diseases | 3 | 2020 | 65 | 0.490 |
Why?
|
| Aged, 80 and over | 29 | 2021 | 5583 | 0.490 |
Why?
|
| Jehovah's Witnesses | 1 | 2015 | 19 | 0.460 |
Why?
|
| Ventricular Dysfunction, Left | 2 | 2007 | 168 | 0.450 |
Why?
|
| Adult | 32 | 2022 | 17271 | 0.440 |
Why?
|
| Heart, Artificial | 1 | 2014 | 2 | 0.440 |
Why?
|
| Cerebrovascular Circulation | 2 | 2014 | 183 | 0.440 |
Why?
|
| Coronary Artery Disease | 4 | 2020 | 322 | 0.430 |
Why?
|
| Perfusion | 1 | 2014 | 75 | 0.420 |
Why?
|
| Atherosclerosis | 2 | 2014 | 160 | 0.420 |
Why?
|
| Risk Factors | 26 | 2021 | 5401 | 0.410 |
Why?
|
| Follow-Up Studies | 16 | 2021 | 2482 | 0.400 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2014 | 66 | 0.400 |
Why?
|
| Transcatheter Aortic Valve Replacement | 4 | 2020 | 110 | 0.390 |
Why?
|
| Proportional Hazards Models | 12 | 2021 | 735 | 0.380 |
Why?
|
| Embolectomy | 4 | 2018 | 15 | 0.380 |
Why?
|
| Survival Rate | 8 | 2019 | 843 | 0.340 |
Why?
|
| Acute Kidney Injury | 4 | 2018 | 142 | 0.340 |
Why?
|
| Heart | 2 | 2022 | 297 | 0.330 |
Why?
|
| Aortic Aneurysm | 5 | 2020 | 81 | 0.320 |
Why?
|
| Ventricular Function, Left | 1 | 2012 | 278 | 0.320 |
Why?
|
| Time Factors | 16 | 2019 | 3750 | 0.310 |
Why?
|
| Heart Diseases | 2 | 2019 | 222 | 0.310 |
Why?
|
| Boston | 8 | 2018 | 257 | 0.300 |
Why?
|
| Atrial Fibrillation | 4 | 2022 | 871 | 0.300 |
Why?
|
| Heart Transplantation | 4 | 2019 | 180 | 0.290 |
Why?
|
| Catheterization | 2 | 2006 | 110 | 0.280 |
Why?
|
| Surgical Wound Infection | 2 | 2021 | 125 | 0.280 |
Why?
|
| Lung Diseases, Interstitial | 2 | 2020 | 144 | 0.270 |
Why?
|
| Coronary Vessels | 2 | 2008 | 123 | 0.270 |
Why?
|
| Cardiovascular Diseases | 1 | 2015 | 861 | 0.270 |
Why?
|
| Hemoglobinopathies | 1 | 2007 | 7 | 0.260 |
Why?
|
| Hemoglobins, Abnormal | 1 | 2007 | 6 | 0.260 |
Why?
|
| Cardiac Valve Annuloplasty | 2 | 2020 | 6 | 0.260 |
Why?
|
| Angioplasty, Balloon, Coronary | 2 | 2004 | 171 | 0.250 |
Why?
|
| Renal Insufficiency, Chronic | 2 | 2019 | 147 | 0.250 |
Why?
|
| Propensity Score | 5 | 2019 | 189 | 0.250 |
Why?
|
| Kaplan-Meier Estimate | 10 | 2018 | 413 | 0.250 |
Why?
|
| Ticlopidine | 3 | 2015 | 47 | 0.240 |
Why?
|
| Myocardial Ischemia | 3 | 2021 | 117 | 0.240 |
Why?
|
| Blood Pressure Monitors | 1 | 2005 | 3 | 0.240 |
Why?
|
| Hypoxia, Brain | 1 | 2005 | 10 | 0.230 |
Why?
|
| Patient Discharge | 3 | 2017 | 518 | 0.230 |
Why?
|
| Platelet Function Tests | 2 | 2015 | 11 | 0.230 |
Why?
|
| Receptors, Purinergic P2Y12 | 2 | 2015 | 7 | 0.230 |
Why?
|
| Age Factors | 10 | 2018 | 1579 | 0.230 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 2 | 2015 | 15 | 0.230 |
Why?
|
| Incidence | 6 | 2021 | 1411 | 0.220 |
Why?
|
| Atherectomy | 1 | 2004 | 8 | 0.220 |
Why?
|
| Length of Stay | 6 | 2021 | 823 | 0.220 |
Why?
|
| Thrombectomy | 1 | 2007 | 253 | 0.220 |
Why?
|
| Atherectomy, Coronary | 1 | 2004 | 12 | 0.220 |
Why?
|
| Heart Neoplasms | 3 | 2012 | 36 | 0.220 |
Why?
|
| Echocardiography | 4 | 2021 | 510 | 0.210 |
Why?
|
| Platelet Aggregation Inhibitors | 3 | 2015 | 233 | 0.210 |
Why?
|
| Blood Platelets | 2 | 2015 | 108 | 0.210 |
Why?
|
| Hematoma | 1 | 2004 | 82 | 0.210 |
Why?
|
| Analgesics, Opioid | 2 | 2019 | 525 | 0.210 |
Why?
|
| Cardiomyopathy, Hypertrophic | 2 | 2023 | 796 | 0.200 |
Why?
|
| Point-of-Care Systems | 2 | 2015 | 126 | 0.200 |
Why?
|
| Hemorrhage | 2 | 2015 | 278 | 0.200 |
Why?
|
| Blood Pressure | 1 | 2005 | 524 | 0.190 |
Why?
|
| Vascular Calcification | 2 | 2014 | 26 | 0.190 |
Why?
|
| Heart Ventricles | 2 | 2016 | 266 | 0.190 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2006 | 223 | 0.190 |
Why?
|
| Severity of Illness Index | 5 | 2020 | 1555 | 0.190 |
Why?
|
| Negative-Pressure Wound Therapy | 1 | 2021 | 12 | 0.180 |
Why?
|
| Opioid-Related Disorders | 2 | 2019 | 524 | 0.180 |
Why?
|
| Ventricular Outflow Obstruction | 1 | 2022 | 118 | 0.170 |
Why?
|
| Mammary Arteries | 1 | 2020 | 11 | 0.170 |
Why?
|
| Suture Techniques | 2 | 2020 | 94 | 0.170 |
Why?
|
| Endarterectomy | 2 | 2012 | 16 | 0.160 |
Why?
|
| Health Facility Size | 1 | 2020 | 16 | 0.160 |
Why?
|
| Hospital Bed Capacity | 1 | 2020 | 27 | 0.160 |
Why?
|
| Thoracic Surgery | 1 | 2021 | 80 | 0.160 |
Why?
|
| Vancomycin | 2 | 2018 | 39 | 0.160 |
Why?
|
| Gene Expression Regulation | 2 | 2017 | 1629 | 0.160 |
Why?
|
| Forecasting | 1 | 2021 | 230 | 0.160 |
Why?
|
| Thoracotomy | 1 | 2020 | 47 | 0.150 |
Why?
|
| Tricuspid Valve Insufficiency | 1 | 2020 | 23 | 0.150 |
Why?
|
| Pulsatile Flow | 1 | 2019 | 10 | 0.150 |
Why?
|
| Glucuronidase | 1 | 2019 | 25 | 0.150 |
Why?
|
| Heart Atria | 3 | 2017 | 137 | 0.150 |
Why?
|
| Transplant Recipients | 1 | 2019 | 31 | 0.150 |
Why?
|
| Heart Valves | 2 | 2017 | 26 | 0.150 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2019 | 61 | 0.150 |
Why?
|
| Thrombolytic Therapy | 2 | 2018 | 195 | 0.150 |
Why?
|
| Medical Staff, Hospital | 1 | 2019 | 59 | 0.150 |
Why?
|
| Contraindications | 3 | 2015 | 52 | 0.150 |
Why?
|
| Wnt Signaling Pathway | 1 | 2019 | 86 | 0.140 |
Why?
|
| Patient Selection | 5 | 2014 | 483 | 0.140 |
Why?
|
| Wound Infection | 1 | 2018 | 29 | 0.140 |
Why?
|
| Postoperative Hemorrhage | 1 | 2018 | 40 | 0.140 |
Why?
|
| Databases, Factual | 5 | 2020 | 881 | 0.140 |
Why?
|
| Heart Arrest, Induced | 2 | 2008 | 13 | 0.130 |
Why?
|
| United States | 6 | 2020 | 8058 | 0.130 |
Why?
|
| Myocardium | 1 | 2019 | 301 | 0.130 |
Why?
|
| Hodgkin Disease | 1 | 2017 | 54 | 0.130 |
Why?
|
| Sinus of Valsalva | 1 | 2016 | 7 | 0.130 |
Why?
|
| Quantitative Trait Loci | 1 | 2017 | 81 | 0.130 |
Why?
|
| Radiation Injuries | 1 | 2017 | 66 | 0.130 |
Why?
|
| Logistic Models | 6 | 2018 | 1267 | 0.120 |
Why?
|
| Cohort Studies | 7 | 2019 | 2607 | 0.120 |
Why?
|
| Registries | 3 | 2016 | 902 | 0.120 |
Why?
|
| Aortic Aneurysm, Thoracic | 1 | 2016 | 108 | 0.120 |
Why?
|
| Cardiac Catheterization | 2 | 2010 | 292 | 0.120 |
Why?
|
| Wound Healing | 1 | 2016 | 193 | 0.110 |
Why?
|
| Alleles | 1 | 2016 | 452 | 0.110 |
Why?
|
| Quality of Health Care | 1 | 2019 | 526 | 0.110 |
Why?
|
| Ultrasonography | 3 | 2012 | 489 | 0.110 |
Why?
|
| Genotype | 1 | 2016 | 672 | 0.110 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2017 | 509 | 0.110 |
Why?
|
| Clinical Competence | 1 | 2019 | 725 | 0.110 |
Why?
|
| Shock, Cardiogenic | 2 | 2005 | 108 | 0.100 |
Why?
|
| Prognosis | 5 | 2018 | 1774 | 0.100 |
Why?
|
| Young Adult | 5 | 2020 | 4782 | 0.100 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2015 | 1653 | 0.100 |
Why?
|
| Quality of Life | 2 | 2011 | 1254 | 0.100 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2017 | 731 | 0.100 |
Why?
|
| Survival Analysis | 4 | 2018 | 575 | 0.100 |
Why?
|
| Lupus Erythematosus, Discoid | 1 | 2012 | 7 | 0.090 |
Why?
|
| Mitral Valve Annuloplasty | 1 | 2012 | 17 | 0.090 |
Why?
|
| Surgical Wound Dehiscence | 1 | 2012 | 16 | 0.090 |
Why?
|
| Constriction | 1 | 2012 | 8 | 0.090 |
Why?
|
| Pulmonary Edema | 1 | 2012 | 29 | 0.090 |
Why?
|
| Coronary Circulation | 1 | 2012 | 55 | 0.090 |
Why?
|
| Heparin | 2 | 2010 | 118 | 0.090 |
Why?
|
| Hemangiosarcoma | 1 | 2012 | 24 | 0.090 |
Why?
|
| Predictive Value of Tests | 4 | 2017 | 1103 | 0.090 |
Why?
|
| Myxoma | 1 | 2011 | 14 | 0.090 |
Why?
|
| Perioperative Care | 1 | 2012 | 86 | 0.080 |
Why?
|
| Embolism, Paradoxical | 1 | 2010 | 14 | 0.080 |
Why?
|
| Comorbidity | 3 | 2016 | 1112 | 0.080 |
Why?
|
| Health Status Indicators | 1 | 2010 | 94 | 0.080 |
Why?
|
| Hemostatic Techniques | 1 | 2009 | 12 | 0.080 |
Why?
|
| Operative Time | 2 | 2020 | 91 | 0.080 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2012 | 372 | 0.080 |
Why?
|
| DNA, Mitochondrial | 1 | 2010 | 86 | 0.080 |
Why?
|
| Adolescent | 5 | 2020 | 6280 | 0.070 |
Why?
|
| Hyperkalemia | 1 | 2008 | 20 | 0.070 |
Why?
|
| Anticoagulants | 2 | 2010 | 522 | 0.070 |
Why?
|
| Recurrence | 2 | 2012 | 654 | 0.070 |
Why?
|
| Survivors | 1 | 2009 | 186 | 0.070 |
Why?
|
| Feasibility Studies | 2 | 2008 | 581 | 0.070 |
Why?
|
| Breast Neoplasms | 1 | 2017 | 1216 | 0.070 |
Why?
|
| Risk | 2 | 2020 | 374 | 0.070 |
Why?
|
| Hospitalization | 3 | 2020 | 1380 | 0.070 |
Why?
|
| Multivariate Analysis | 3 | 2016 | 928 | 0.070 |
Why?
|
| DNA Replication | 1 | 2010 | 247 | 0.070 |
Why?
|
| Stroke | 3 | 2018 | 1207 | 0.060 |
Why?
|
| Ischemic Attack, Transient | 1 | 2008 | 96 | 0.060 |
Why?
|
| Combined Modality Therapy | 2 | 2021 | 370 | 0.060 |
Why?
|
| Erythrocyte Transfusion | 1 | 2007 | 78 | 0.060 |
Why?
|
| Ultrasonography, Interventional | 1 | 2008 | 119 | 0.060 |
Why?
|
| Academic Medical Centers | 2 | 2019 | 302 | 0.060 |
Why?
|
| Mitochondria | 1 | 2010 | 401 | 0.060 |
Why?
|
| Hypertension, Pulmonary | 1 | 2007 | 99 | 0.060 |
Why?
|
| Shock | 1 | 2006 | 33 | 0.060 |
Why?
|
| Blood Transfusion | 1 | 2007 | 164 | 0.060 |
Why?
|
| Anesthesia, General | 1 | 2006 | 47 | 0.060 |
Why?
|
| Axillary Artery | 1 | 2005 | 7 | 0.060 |
Why?
|
| Aortography | 1 | 2006 | 58 | 0.060 |
Why?
|
| Body Surface Area | 1 | 2005 | 11 | 0.060 |
Why?
|
| Femoral Vein | 1 | 2005 | 19 | 0.060 |
Why?
|
| Thromboembolism | 1 | 2006 | 74 | 0.060 |
Why?
|
| Intraoperative Care | 1 | 2005 | 38 | 0.060 |
Why?
|
| Hypothermia, Induced | 1 | 2005 | 39 | 0.060 |
Why?
|
| Stroke Volume | 1 | 2007 | 342 | 0.060 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2017 | 312 | 0.060 |
Why?
|
| Femoral Artery | 1 | 2006 | 104 | 0.060 |
Why?
|
| Pericardiocentesis | 1 | 2004 | 4 | 0.060 |
Why?
|
| Postoperative Care | 1 | 2005 | 125 | 0.060 |
Why?
|
| Radial Artery | 1 | 2005 | 55 | 0.050 |
Why?
|
| Coronary Restenosis | 1 | 2004 | 21 | 0.050 |
Why?
|
| Electroencephalography | 1 | 2005 | 149 | 0.050 |
Why?
|
| Cardiac Tamponade | 1 | 2004 | 14 | 0.050 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2004 | 60 | 0.050 |
Why?
|
| Postoperative Period | 2 | 2017 | 130 | 0.050 |
Why?
|
| Fatal Outcome | 1 | 2004 | 122 | 0.050 |
Why?
|
| Emergencies | 1 | 2004 | 122 | 0.050 |
Why?
|
| Foreign Bodies | 1 | 2004 | 55 | 0.050 |
Why?
|
| Pacemaker, Artificial | 1 | 2004 | 50 | 0.050 |
Why?
|
| Cerebral Cortex | 1 | 2005 | 267 | 0.050 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2005 | 214 | 0.050 |
Why?
|
| Odds Ratio | 3 | 2012 | 754 | 0.050 |
Why?
|
| Disease Progression | 2 | 2018 | 1214 | 0.050 |
Why?
|
| Heart Arrest | 1 | 2005 | 175 | 0.050 |
Why?
|
| Leukemia-Lymphoma, Adult T-Cell | 1 | 2002 | 10 | 0.050 |
Why?
|
| Bone Wires | 1 | 2021 | 5 | 0.050 |
Why?
|
| ROC Curve | 2 | 2015 | 292 | 0.040 |
Why?
|
| Bone Plates | 1 | 2021 | 41 | 0.040 |
Why?
|
| Acute Disease | 2 | 2018 | 663 | 0.040 |
Why?
|
| Internal Mammary-Coronary Artery Anastomosis | 1 | 2020 | 4 | 0.040 |
Why?
|
| Stents | 1 | 2004 | 493 | 0.040 |
Why?
|
| Surgical Flaps | 1 | 2021 | 116 | 0.040 |
Why?
|
| Transplantation, Homologous | 1 | 2021 | 250 | 0.040 |
Why?
|
| Dyspnea | 2 | 2011 | 120 | 0.040 |
Why?
|
| Aortic Rupture | 1 | 2020 | 47 | 0.040 |
Why?
|
| Thoracic Surgical Procedures | 1 | 2020 | 42 | 0.040 |
Why?
|
| Massachusetts | 2 | 2019 | 2140 | 0.040 |
Why?
|
| Hospital Costs | 1 | 2020 | 126 | 0.040 |
Why?
|
| Tissue and Organ Procurement | 1 | 2019 | 39 | 0.040 |
Why?
|
| Benchmarking | 1 | 2020 | 136 | 0.040 |
Why?
|
| Morbidity | 1 | 2019 | 110 | 0.040 |
Why?
|
| Child | 3 | 2022 | 4601 | 0.040 |
Why?
|
| Risk Adjustment | 1 | 2019 | 94 | 0.040 |
Why?
|
| Hospitals, Teaching | 1 | 2019 | 105 | 0.040 |
Why?
|
| Myocytes, Cardiac | 1 | 2019 | 121 | 0.040 |
Why?
|
| Fibrosis | 1 | 2019 | 172 | 0.040 |
Why?
|
| Seasons | 1 | 2019 | 138 | 0.040 |
Why?
|
| Hospitals | 1 | 2021 | 385 | 0.040 |
Why?
|
| Trachea | 1 | 1998 | 83 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2016 | 3300 | 0.030 |
Why?
|
| Chi-Square Distribution | 2 | 2010 | 414 | 0.030 |
Why?
|
| Restraint, Physical | 1 | 2018 | 57 | 0.030 |
Why?
|
| Ventricular Dysfunction, Right | 1 | 2018 | 50 | 0.030 |
Why?
|
| NAV1.8 Voltage-Gated Sodium Channel | 1 | 2017 | 3 | 0.030 |
Why?
|
| Sex Factors | 1 | 2020 | 990 | 0.030 |
Why?
|
| Radiotherapy | 1 | 2017 | 65 | 0.030 |
Why?
|
| Cyclic GMP | 1 | 2017 | 33 | 0.030 |
Why?
|
| Ointments | 1 | 2016 | 7 | 0.030 |
Why?
|
| Monitoring, Intraoperative | 2 | 2008 | 47 | 0.030 |
Why?
|
| Venous Thrombosis | 1 | 2018 | 112 | 0.030 |
Why?
|
| Administration, Topical | 1 | 2016 | 50 | 0.030 |
Why?
|
| Body Size | 1 | 2016 | 19 | 0.030 |
Why?
|
| Dilatation, Pathologic | 1 | 2016 | 30 | 0.030 |
Why?
|
| Genotyping Techniques | 1 | 2016 | 21 | 0.030 |
Why?
|
| Membrane Potentials | 1 | 2017 | 138 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2021 | 432 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2017 | 120 | 0.030 |
Why?
|
| Inpatients | 1 | 2019 | 313 | 0.030 |
Why?
|
| Muscle Proteins | 1 | 2017 | 117 | 0.030 |
Why?
|
| Patient Readmission | 1 | 2020 | 446 | 0.030 |
Why?
|
| Education, Medical, Graduate | 1 | 2019 | 348 | 0.030 |
Why?
|
| Reference Values | 1 | 2016 | 326 | 0.030 |
Why?
|
| Kidney | 1 | 2018 | 450 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2017 | 180 | 0.030 |
Why?
|
| Tertiary Care Centers | 1 | 2016 | 110 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2019 | 741 | 0.030 |
Why?
|
| Cardiovascular Agents | 1 | 2016 | 106 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2019 | 2183 | 0.030 |
Why?
|
| Area Under Curve | 1 | 2015 | 149 | 0.030 |
Why?
|
| Drug Resistance | 1 | 2015 | 152 | 0.030 |
Why?
|
| Home Care Services | 1 | 2013 | 97 | 0.020 |
Why?
|
| Biomarkers | 1 | 2018 | 1472 | 0.020 |
Why?
|
| Phenotype | 1 | 2016 | 1231 | 0.020 |
Why?
|
| Carrier Proteins | 1 | 2017 | 718 | 0.020 |
Why?
|
| Counterpulsation | 1 | 2012 | 2 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2012 | 242 | 0.020 |
Why?
|
| Internship and Residency | 1 | 2019 | 804 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2015 | 1009 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2012 | 221 | 0.020 |
Why?
|
| Scoliosis | 1 | 2011 | 10 | 0.020 |
Why?
|
| Tinnitus | 1 | 2011 | 16 | 0.020 |
Why?
|
| Alopecia | 1 | 2011 | 28 | 0.020 |
Why?
|
| Dipyridamole | 1 | 2010 | 17 | 0.020 |
Why?
|
| Elective Surgical Procedures | 1 | 2011 | 119 | 0.020 |
Why?
|
| Databases as Topic | 1 | 2010 | 49 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2012 | 539 | 0.020 |
Why?
|
| Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | 1 | 2010 | 34 | 0.020 |
Why?
|
| Thrombocytopenia | 1 | 2010 | 56 | 0.020 |
Why?
|
| Whole Blood Coagulation Time | 1 | 2009 | 3 | 0.020 |
Why?
|
| Secondary Prevention | 1 | 2010 | 164 | 0.020 |
Why?
|
| Heat-Shock Proteins | 1 | 2010 | 69 | 0.020 |
Why?
|
| Linear Models | 1 | 2010 | 405 | 0.020 |
Why?
|
| Aspirin | 1 | 2010 | 171 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2009 | 206 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2010 | 324 | 0.020 |
Why?
|
| Surgical Instruments | 1 | 2008 | 44 | 0.020 |
Why?
|
| Mediastinum | 1 | 2008 | 28 | 0.020 |
Why?
|
| Case-Control Studies | 1 | 2012 | 1134 | 0.020 |
Why?
|
| Dissection | 1 | 2008 | 46 | 0.020 |
Why?
|
| Diastole | 1 | 2008 | 90 | 0.020 |
Why?
|
| Walking | 1 | 2010 | 242 | 0.020 |
Why?
|
| Myocardial Revascularization | 1 | 2008 | 78 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2009 | 853 | 0.020 |
Why?
|
| Probability | 1 | 2008 | 168 | 0.020 |
Why?
|
| Neoplasms | 1 | 2018 | 1362 | 0.020 |
Why?
|
| Coronary Stenosis | 1 | 2008 | 41 | 0.020 |
Why?
|
| Animals | 2 | 2016 | 21259 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2017 | 3137 | 0.020 |
Why?
|
| Coronary Artery Bypass, Off-Pump | 1 | 2005 | 5 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 2006 | 236 | 0.010 |
Why?
|
| Algorithms | 1 | 2010 | 1040 | 0.010 |
Why?
|
| Angiography | 1 | 2005 | 154 | 0.010 |
Why?
|
| Myocardial Infarction | 1 | 2012 | 918 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2006 | 497 | 0.010 |
Why?
|
| Anastomosis, Surgical | 1 | 2005 | 118 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2009 | 1689 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2008 | 1160 | 0.010 |
Why?
|
| Mice | 1 | 2016 | 11070 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2010 | 1549 | 0.010 |
Why?
|
| Tracheal Stenosis | 1 | 1998 | 9 | 0.010 |
Why?
|
| Bronchoscopy | 1 | 1998 | 88 | 0.010 |
Why?
|